In silico antibody accessibility analysis indicates that ectodomain epitopes are transiently exposed, while MPER epitopes are virtually always occluded in the pre-fusion trimer.

PPA constraints need to be paired with real workloads, but they also need to be flexible to account for future changes.

Clinical trials continue to be a driving force in ophthalmology, propelling the development of innovative treatments and technologies that improve patient outcomes. Editor’s Note: This is part three ...